Pectus cancer
With the advancement of breast cancer diagnosis and treatment, the survival time of breast cancer patients has prolonged significantly, but the incidence of breast cancer brain metastases (BCBM) has gradually increased. This article reviews recent clinical studies related to the survival prognosis and treatment of breast metastases from breast cancer. It is generally believed that factors such as age, KPS score, receptor status, number of brain metastases, and control of extracranial lesions affect patient prognosis. Surgery, whole brain radiotherapy (WBRT), and stereotactic radiosurgergy (SRS) are currently the first-line treatments for brain metastases. With the development of comprehensive pectus cancer treatment, the application of chemotherapy and molecular targeted therapy in breast metastasis has received more and more attention.
Pectus cancer metastasis de cerebri
In annis, cum continua emendationem diagnosis et curatio et salvos tempus aegris est significantly per patientiam sustentatur; et incidit in cerebrum metastases (metastasis cerebrum, BM) etiam augetur. About XXX% de aegris cerebrum mos eventually develop metastases, et salvos metastases tempus est II ~ XIV menses post cerebrum. Pectus cancer metastasis cerebrum non habet excelsum incidentiae de deploratae et pauper. Facti sunt non est magni momenti factor afficiens vita, et qualis salvos. Et deploratae et curatio ex BM ad focus fuit semper, et est difficultas in circulos academic. Is est maximus resolvere habet et orci ejus invenire efficax curatio est. Et urgente opus. Hic articulus ex curatio, et deploratae BCBM recenset orci.
Pronostico factores pro pectus cancer a cerebri metastases
Quidam studiis ostendimus, deploratae est ad BCBM autem factores talis ut aetate, genere hypothetica, extracranial metastasis, tum ex BM numerus laesiones, vitio id experiundum est maxime area, et KPS ustulo. Inquisitores statutum prognosticon iudicium alia exempla monstrabit, fundatur super hoc quod movet eorundem trying ut distinguere efficientius Cum aegris cerebrum metastases prognosticon diversis Insidijs ad auxilium arbitrium a orci.
Metastatic pectus cancer curatio de cerebri
Quod est curatio cerebri metastases de pectus cancer, oportet esse comprehensum ut sunt existimandi secundum communem patientes estote ad condicionem, in locum laesionem, et in conspectu extracranial potestate statuendi de treatment consilium. Hoc tempore, surgery, WBRT, SRS sunt etiam primo-curatio est recta BCBM. Chemotherapy et profectum etiam in maligno targeted therapies.
Lorem hormone pro pectus cancer metastatic
The commonly used drug is dexamethasone, and hormone therapy is not required for patients with asymptomatic brain metastases. Dexamethasone can relieve the symptoms caused by edema in a short time by restoring the elasticity of arterial blood vessels and reducing the permeability of capillaries. The recommended starting dose of dexamethasone is 4 ~ 8mg / d; when brain metastases are secondary to severe cerebral edema and high intracranial pressure, it is recommended to use dexamethasone at a dose of 16mg / d or greater, which should be gradually reduced when discontinued. the amount.
Chirurgicam curatio de pectus cancer metastatic
Est maxime idoneam ad singula aegris ictibus exactis occidentes et KPS> 70 Amet, XX% -20% de aegris manu curandum esset faciendum idoneos carpunt. Sunt qui sua commoda possit cito sublevare signa, beneficia pathologi- cum st ^ specimen et loci imperium meliorem rate. Cerebrum surgery est status apud plures relevant notitia quod adhuc usque deest metastases erit perfectius fundamentum.
Rectum totum cerebrum
For patients with intracranial lesions> 3, the total effective rate of whole-brain radiotherapy alone was 60 to 80%. About 70% of patients had improved symptoms and prolonged the average survival time of 3 to 6 months. Stereotactic Radiosurgery (SRS)It is generally believed that SRS is mainly suitable for patients with 3 or less lesions, a diameter of <3.0 cm, and a small space effect, especially for tumors that are not easily accessible during surgery and are located in important functional areas. But SRS has been studied more and more in multiple brain metastases, and it seems feasible.
Plasmodium falciparum pro pectus cancer metastatic
The efficacy of chemotherapy on BCBM is limited because the drug has difficulty crossing the blood-brain barrier. Some studies in recent years have shown that the combination of chemotherapy and radiotherapy can improve the efficacy. Because radiation therapy opens the blood-brain barrier, drugs can enter the skull to exert anti-tumor effects. Although chemotherapeutic drugs are difficult to achieve a clear antitumor effect in the skull, effective control of extracranial lesions can improve the quality of life and prolong the survival time of patients.
Lorem targeted pro pectus cancer metastatic
With the continuous understanding of the mechanism of tuberculum formation and metastasis, molecular targeted therapy has become a routine treatment strategy for malignant tumors. Bevacizumab combined with radiotherapy is mainly used for the treatment of gliomas, and there are few studies in brain metastases such as breast cancer and lung cancer, and further research is still needed.
Lorem glandularum endocrinarum pro pectus cancer metastatic
There is very little research data on endocrine therapy in BCBM treatment. Because endocrine therapy has a slower onset of action, and most patients with BM have a poor prognosis and need to control local symptoms as soon as possible, endocrine therapy is not recommended as first-line treatment for BCBM. In summary. The high incidence and poor prognosis of brain metastases in breast cancer have become clinically difficult problems. It is generally believed that factors such as age, KPS score, receptor status, number of brain metastases, and stability of extracranial lesions affect the prognosis of patients, but the current prognostic assessment model has limited predictive power and needs to be further improved and improved. In terms of treatment, surgery and radiation therapy are still the main treatment methods, and the status of chemotherapy and molecular targeted drugs has gradually increased.
